Is giving Tenecteplase (TNK) appropriate for a patient with vertebral artery dissection, and what is the recommended management?

Giving TNK to a Patient with Vertebral Artery Dissection: Was This Correct?

Administering TNK (tenecteplase) to a patient with vertebral artery dissection was likely inappropriate and potentially dangerous, as vertebral artery dissection is NOT an FDA-approved indication for thrombolytic therapy, and the risk of hemorrhagic transformation or extension of the dissection poses significant mortality risk.

The Critical Problem

The FDA label for TNKase explicitly states it is indicated only for acute ST-elevation myocardial infarction (STEMI) 1. There is no approved indication for stroke caused by arterial dissection. More importantly, TNKase carries a black-box warning for bleeding complications, including intracranial hemorrhage and fatal bleeding 1. In vertebral artery dissection, the vessel wall is already compromised with an intramural hematoma—administering a thrombolytic could theoretically worsen the dissection or cause catastrophic bleeding.

Why This Matters for Morbidity and Mortality

• Hemorrhagic risk: TNKase significantly increases bleeding risk, and a dissected artery with disrupted vessel wall integrity is at high risk for rupture or extension 1
• No guideline support: The 2018 AHA/ASA Stroke Guidelines discuss TNK only in the context of atherosclerotic ischemic stroke, not arterial dissection 2
• Dissection-specific pathology: Unlike atherosclerotic stroke where clot lysis is beneficial, dissection involves vessel wall injury where anticoagulation or antiplatelet therapy is the standard approach 3, 4

Current Evidence on TNK in Vertebral Artery Dissection

There is one case report from 2025 describing TNK use in a patient with vertebral artery dissection who presented with focal neurologic deficits 5. The authors themselves acknowledge: "Currently, no official guidelines exist to recommend treatment of VAD with thrombolytics, as no randomized controlled trial has been done to show this is an effective and safe treatment" 5. This is anecdotal evidence at best and should not guide clinical practice when mortality is at stake.

Correct Management of Vertebral Artery Dissection

The standard of care for vertebral artery dissection presenting with ischemic symptoms is antithrombotic therapy—either anticoagulation or antiplatelet agents—NOT thrombolysis 3, 6, 4.

Immediate Management Algorithm:

1. Confirm diagnosis with imaging:

   • MRI/MRA is preferred for diagnosis
   • Look for intramural hematoma on T1-weighted black-blood sequences (most reliable sign) 4
   • DSA (digital subtraction angiography) remains gold standard if diagnosis uncertain 4

2. Assess for hemorrhagic vs. ischemic presentation:

   • Ischemic presentation (headache, neck pain, posterior circulation stroke symptoms): Proceed with antithrombotic therapy
   • Hemorrhagic presentation (subarachnoid hemorrhage): Neurosurgical consultation, avoid anticoagulation

3. Initiate antithrombotic therapy for ischemic VAD:

   • Option 1: Anticoagulation with heparin followed by warfarin or direct oral anticoagulants (e.g., high-dose apixaban) 3
   • Option 2: Antiplatelet therapy with aspirin alone or dual antiplatelet therapy 3, 6
   • Duration: Typically 3-6 months, then transition to aspirin monotherapy 6
   • Rationale: Prevents thromboembolic complications from the dissection site

4. Monitor for progression:

   • Serial neurological exams
   • Repeat imaging if symptoms worsen
   • Some patients may require escalation from antiplatelet to anticoagulation if infarcts progress despite initial therapy 6

Common Pitfalls to Avoid:

• Do NOT give thrombolytics for arterial dissection—this is off-label, unsupported by guidelines, and carries hemorrhagic risk
• Do NOT delay antithrombotic therapy once diagnosis is confirmed and hemorrhage excluded
• Do NOT miss the diagnosis: Maintain high suspicion in young patients with posterior neck pain and neurologic symptoms, even after minor trauma 3
• Do NOT assume MRA is always diagnostic: Initial MRA can be falsely negative; if clinical suspicion is high, proceed to DSA 6

What Should Happen Now for This Patient?

1. Immediate assessment:

   • Urgent neuroimaging (CT head to rule out hemorrhage, MRI/MRA to confirm dissection and assess for infarction)
   • Neurological examination every 1-2 hours for first 24 hours post-TNK

2. If no hemorrhagic complication has occurred:

   • Start antiplatelet therapy (aspirin 325 mg loading dose, then 81-325 mg daily) or anticoagulation based on extent of dissection and thrombus burden
   • Monitor closely for signs of bleeding given recent TNK administration

3. If hemorrhagic complication develops:

   • Discontinue all antithrombotics immediately
   • Reverse anticoagulation if applicable
   • Neurosurgical consultation
   • Supportive care per hemorrhagic stroke protocols 1

Bottom line: This was a high-risk decision that deviated from standard care. The patient needs close monitoring for the next 24-36 hours for symptomatic intracranial hemorrhage (occurs in 2.8% even in appropriate TNK candidates 7), and should be transitioned to guideline-concordant antithrombotic therapy for vertebral artery dissection management.